Logo image
Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium
Journal article   Open access   Peer reviewed

Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium

Prerna Rastogi and Jane McHowat
Respiratory physiology & neurobiology, Vol.165(2-3), pp.167-174
02/28/2009
DOI: 10.1016/j.resp.2008.11.006
PMCID: PMC2845306
PMID: 19059366
url
http://doi.org/10.1016/j.resp.2008.11.006View
Open Access

Abstract

Inhalation of allergens can result in mast cell degranulation and release of granule contents, including tryptase, in the lung. Injury to human pulmonary microvascular endothelial cells (HMVEC-L) can also result in activation of the coagulation cascade and thrombin generation. We hypothesize that these proteases activate calcium-independent phospholipase A2 (iPLA2), in HMVEC-L, leading to the production of membrane phospholipids-derived inflammatory mediators. Both thrombin and tryptase stimulation of HMVEC-L increased iPLA2 activity that was inhibited by pretreatment with the iPLA2 selective inhibitor bromoenol lactone (BEL). Arachidonic acid and prostaglandin I2 (PGI2) release were also increased in tryptase and thrombin stimulated cells and inhibited by BEL pretreatment. Pretreating the endothelial cells with AACOCF3 a cytosolic PLA2 inhibitor did not inhibit tryptase or thrombin induced arachidonic acid and PGI2 release. In addition thrombin and tryptase also increased HMVEC-L platelet activating factor (PAF) production that significantly contributes to the recruitment and initial adherence of polymorphonuclear neutrophils (PMN) to the endothelium. Tryptase or thrombin stimulated increase in PMN adherence to the endothelium was inhibited by pretreatment of HMVEC-L with BEL or pretreatment of PMN with CV3988, a PAF receptor specific antagonist. Collectively, these data support our hypothesis that iPLA2 activity is responsible for membrane phospholipid hydrolysis in response to tryptase or thrombin stimulation in HMVEC-L. Therefore selective inhibition of iPLA2 may be a pharmacological target to inhibit the early inflammation in pulmonary vasculature that occurs as a consequence of mast cell degranulation or acute lung injury.
Neutrophils - cytology Arachidonic Acid - metabolism Epoprostenol - metabolism Humans Cells, Cultured Hypersensitivity - immunology Phosphodiesterase Inhibitors - pharmacology Cell Adhesion - drug effects Enzyme Activation - drug effects Group VI Phospholipases A2 - metabolism Pyrones - pharmacology Naphthalenes - pharmacology Cell Adhesion - immunology Endothelial Cells - immunology Platelet Activating Factor - metabolism Thrombin - pharmacology Group VI Phospholipases A2 - antagonists & inhibitors Hypersensitivity - metabolism Endothelial Cells - cytology Inflammation Mediators - metabolism Tryptases - pharmacology Lung - blood supply Endothelial Cells - enzymology Enzyme Activation - physiology

Details

Metrics

Logo image